Eurofins completed divestment while Eurofins stock sits 3.79 percent below its high

Published on 10/09/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eurofins stock costs EUR 76.22 on October 9, 2026 after EUR 75.51, plus 0.94 percent. The high is EUR 79.22 and the low EUR 54.86.

Key points in brief

Eurofins completed the divestment of its Electrical and Electronic Testing business to UL Solutions on October 1, 2026 for EUR 575.0 million.
The company also completed the acquisition of Element's North American Life Sciences Testing Services business for USD 400.0 million.
Eurofins stock was trading at EUR 76.22 at Lang & Schwarz on October 9, 2026, plus 0.94 percent versus the EUR 75.51 prior close.
Goldman Sachs kept a buy view and raised its target from EUR 85.00 to EUR 89.00, according to a report dated October 2, 2026.

Aquarellillustration der Altstadt und Skyline von Luxembourg mit Fluss und Brücken — Aquarellmalerei von Luxembourg symbolisiert den Sitz von Eurofins Scientific SE, ISIN FR0014000MR3, in Pastelltönen, Illustration mit AI erstellt.

Eurofins (ISIN FR0014000MR3) was trading at EUR 76.22 at Lang & Schwarz on October 9, 2026 at 12:01 p.m. CEST, plus 0.94 percent versus the EUR 75.51 prior close. The company completed the divestment of its Electrical and Electronic Testing business on October 1, 2026 for an enterprise value of EUR 575.0 million, according to FinanzNachrichten.

Three dates shape the story

Eurofins reported H1 2026 results on July 23, with adjusted EBITDA margin expansion of 130 basis points and earnings per share growth of 29.00 percent, according to Eurofins. On October 1, 2026, it completed the acquisition of Element Materials Technology's North American Life Sciences Testing Services business for an enterprise value of USD 400.0 million, according to FinanzNachrichten. The divestment followed on the same date, leaving portfolio reshaping as the clearest company-specific event for the stock.

What does the portfolio shift change

The divestment releases EUR 575.0 million of enterprise value from a business with about 1,300 employees, while the acquisition adds North American testing capacity expected to generate over USD 150.0 million of revenue in 2026. The two transactions point capital toward food, environmental, pharmaceutical, clinical and related testing, while the acquired Element operations add 27 laboratories and facilities in the United States and Canada, according to FinanzNachrichten.

For investors, the contrast is between portfolio focus and execution risk. Eurofins has linked the proceeds to debt reduction, laboratory capital expenditure, digital solutions, robotics, artificial intelligence, share buybacks and strategic acquisitions, while the acquired business must be integrated into the existing hub-and-spoke network.

Goldman Sachs raises its target

Goldman Sachs kept a buy view on Eurofins and raised its target from EUR 85.00 to EUR 89.00, according to Ideal Investisseur in a report published October 7, 2026 that identified the analyst change as October 2. The EUR 89.00 target is 16.77 percent above the Lang & Schwarz price of EUR 76.22.

Stock remains below its yearly high

Eurofins stock was trading at EUR 76.22 at Lang & Schwarz on October 9, 2026 at 12:01 p.m. CEST, plus 0.94 percent versus the EUR 75.51 prior close. The price was 3.79 percent below the 52-week high of EUR 79.22 and above the 52-week low of EUR 54.86. The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.